Our Website Uses Cookies
We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.
For more information, please contact us or consult our Privacy Notice.
Your binder contains too many pages, the maximum is 40.
We are unable to add this page to your binder, please try again later.
This page has been added to your binder.
李唯实是本所生命科学交易业务团队的一名合伙人。她的业务领域主要涉及生命科学客户的交易事项。她经常为中国生命科学公司组织和谈判涉及中国的跨境商业、公司和合伙交易,包括战略合作、合资经营、许可、收购、共同推广及分销安排 。李律师是美国注册专利律师,拥有微生物学博士学位以及丰富的食品和药品监管方面的经验。因此,她对于行业面临的复杂问题有着深入的了解,而且非常擅长帮助客户处理此类问题。
June 18, 2019, Covington Alert
On June 10, 2019, the State Council (China’s chief executive agency) promulgated the long-awaited Regulation on the Administration of Human Genetic Resources (the “Regulation”), which will become effective on July 1, 2019. The Regulation supersedes the currently effective regulations and guidance on human genetic resources (“HGR”).
April 8, 2019, Covington Alert
On March 15, 2019, China’s National People’s Congress voted to adopt a new Foreign Investment Law (the “FIL”). The FIL will come into effect on January 1, 2020 and may significantly change China’s framework for regulating foreign investment. Foreign invested entities (“FIEs”) established prior to the FIL’s effective date will have five years to amend their ...
March 27, 2018, Covington Alert
China has reorganized many of the ministries and commissions under its chief executive body, the State Council, creating a new super-ministry to replace the China Food and Drug Administration (“CFDA”) and other healthcare agencies.
November 6, 2017, Covington Alert
China has recently announced several initiatives to reform its regulation of drugs and medical devices that could have a significant impact on pharmaceutical and medical device companies doing business in China.
May 23, 2017, Covington Alert
On May 11 and 12, 2017, the China Food and Drug Administration (“CFDA”) published drafts of four proposed policies in the form of circulars (or notices) for public comment. These “Proposed Policies” include significant reforms in the areas of the new drug and device approval process (“Circular 52”), clinical trial regulation (“Circular 53”), life-cycle ...
January 23, 2017, Covington Alert
On January 9, 2017, eight Chinese ministries announced a significant new policy that aims to reduce marked-up prices and corruption in multi-tier distribution chains. The policy effectively requires that under most circumstances, at most two invoices may be issued throughout the distribution chain, with one from the manufacturer to a distributor and another from ...
December 21, 2016
SHANGHAI—China Business Law Journal has named Covington partner Weishi Li to its “A-List” of the top 100 private practice lawyers in China. Ms. Li is one of two life sciences lawyers recognized by the magazine. China Business Law Journal’s inaugural A-list is based on interviews of in-house counsel in China and around the world, as well as partners at Chinese ...
Life Sciences Cross-border Partnering and M&A Transactions: Overcoming Legal and Regulatory Obstacles
September 21, 2016
Covington Opens Shanghai Office
January 9, 2013
WASHINGTON, DC, January 9, 2013 — Covington & Burling has launched its Shanghai office, its third in Asia, following the opening of offices in Beijing in 2008 and Seoul in late 2012. The firm will now have a total of 20 lawyers resident in these three offices, placing it among AmLaw’s Top 50 U.S. firms with a presence in Asia. The move strengthens the firm’s ...
September 5, 2012
WASHINGTON, DC, September 5, 2012 — Covington & Burling is pleased to announce the addition of Weishi Li as a partner to its corporate team, further bolstering the firm’s global transactional and IP capabilities in the life sciences and technology sectors. Ms. Li will be based in Shanghai when that office opens. Ms. Li’s practice covers a wide range of ...
- 《商法》, 大中华区: 中国法律精英100强 (2016)
- 《钱伯斯亚太指南》,中国:生命科学 (国际律师事务所,第一梯队) (2012-2019)
- 《钱伯斯全球》及全球:生命科学 (2014-2016)
- 《亚洲知识产权专家》, 许可及特许经营; 医药及生物科技 (2014, 2017)
- 《生命科学律师国际名人录》(2011-2015)
- 《知识资产管理-专利领域1000强》,世界一流的专利和技术许可律师
- 《知识资产管理-许可领域250强》,世界一流的专利和技术许可律师